TNFRSF10B and bacterial infectious disease: To test this directly, we blocked TRAIL–DR5 interaction by use of a blocking antibody and found that anti-TRAIL treatment throughout viral and secondary bacterial infection (1–9 dpi) ameliorated the outcome of low-dose coinfection (Fig3C).